Prospective Multicenter Study of Genetic Factors Predictive of the Pharmacodynamics of Trastuzumab in Patients With Metastatic Breast Cancer
- To evaluate the predictive value of genetic factors on the toxicity and efficacy of a
trastuzumab-based therapy in women with metastatic breast cancer.
- To analyze tumor factors potentially related to the efficacy of trastuzumab (i.e.,
expression of proteins involved in cell proliferation and survival).
OUTLINE: This is a multicenter study.
Patients receive standard treatment with trastuzumab. Blood is collected periodically for
Primary Purpose: Treatment
Toxicity, including cardiotoxicity and immuno-allergic reactions
Jean Marc Ferrero, MD
Centre Antoine Lacassagne